The group's principal activities consist of research, development, commercialization, licensing and sales of innovative drug products and antibody generation services. The group's subsidiary xenerex biosciences is developing completely human antibody products to target antigens causing various ailments. The group also carries out clinical development of neurodex a drug for treatment of several central nervous systems disorders. Other researches include for the treatment of allergies, asthma and cholesterol reduction. The group has entered into marketing license agreements with glaxosmithkline in North America, boryung pharmaceuticals in South Korea and cts chemical industries in Israel.
